Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts

Journal of the National Cancer Institute

Volumn 90, Issue 7, 1998, Pages 505-511

  Zamboni, William C ^a   Stewart, Clinton F ^b   Thompson, Joyce ^a   Santana, Victor M ^a   Cheshire, Pamela J ^a   Richmond, Lois B ^a   Luo, Xiaolong ^a   Poquette, Catherine ^a   Houghton, Janet A ^a   Houghton, Peter J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NEUROBLASTOMA; NONHUMAN; XENOGRAFT;

EID: 0032054147     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.7.505     Document Type: Article

References (22)

1. Houghton PJ, Houghton JA, Myers L, Cheshire P, Howbert JJ, Grindey GB. Evaluation of N-(5-indanylsulfonyl)-N′-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma. Cancer Chemother Pharmacol 1989;25:84-8.
2. Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW, Houghton JA. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 1992;31:229-39.
3. Houghton PJ, Cheshire PJ, Hallman JD 2nd, Lutz L, Friedman HS, Danks MK, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36: 393-403.
4. Friedman HS, Houghton PJ, Schold SC, Keir S, Bigner DD. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 1994;34:171-4.
5. Thompson J, Stewart C, Zamboni W, Houghton PJ. Systemic exposure to topotecan related to antitumor response in human neuroblastoma xenografts [abstract]. Proc Am Assoc Cancer Res 1997;38:305.
6. Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, Ochs J, et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 1994;12:539-43.
7. Tubergen DG, Stewart CF, Pratt CB, Zamboni WC, Winick N, Santana VM, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 1996;18:352-61.
8. Kretschmar C, Kletzel M, Murray K, Joshi V, Smith E, Pao PV, et al. Upfront phase II therapy with taxol (Txl) and topotecan (Topo) in untreated children (>365 days) with disseminated (INSS stage 4) neuroblastoma (NB). A pediatric Oncology Group (POG) study [abstract]. Med Pediatr Oncol 1995;25:243.
9. Houghton JA, Houghton PJ. Rodent tumor models in experimental cancer therapy. In: Kallman R, editor. The suitability and use of human tumor xenografts. Elmsford (NY): Pergamon Press; 1987:199-204.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
11. Lehman E. Nonparametrics: statistical methods based on ranks. San Francisco: Holden-Day Inc., 1975.
12. Furman WL, Baker SD, Pratt CB, Rivera GK, Evans WE, Stewart CF. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J Clin Oncol 1996;14:1504-11.
13. Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A, Stewart CF. Cerebrospinal fluid pharmacokinetics and penetration of continuous-infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol 1996;37:195-202.
14. Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol 1994;12: 1946-54.
15. D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 1979;9:115-34.
16. Gibaldi M, Perrier D. Pharmacokinetics. 2nd. New York: Marcel Dekker; 1982.
17. Evans WE, Relling MV. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 1989;16:327-36.
18. Evans WE, Rodman JH, Relling MV, Crom WR, Rivera GK, Pratt CB. Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugs. Med Pediatr Oncol 1991;19:153-9.
19. Evans WE, Stewart CF, Hutson PR, Cairnes DA, Bowman WP, Yee GC, et al. Disposition of intermediate-dose methotrexate in children with acute lymphocytic leukemia. Drug Intell Clin Pharm 1982;16:839-42.
20. Rodman JH, Murry DJ, Madden T, Santana VM. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol 1994;12:2390-7.
21. Rodman JH, Relling MV, Stewart CF, Synold TW, McLeod H, Kearns C, et al. Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children. Semin Oncol 1993;20:18-29.
22. Thompson J, Zamboni WC, Cheshire PJ, Lutz L, Luo X, Li Y, et al. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 1997;3:423-31.